Migraine affects an estimated 1.1 billion people worldwide and ranks as the 2nd leading cause of disability, while being the leading among young adults.1,2,3 There is a female predominance of approximately 2:1, and the prevalence surges throughout puberty, peaks around age forty, and finally declines in the elderly. Migraine without aura is the most common form, whereas a third experience attacks of migraine with aura either exclusively or in addition to attacks without aura.
Related content
Discover how human models of migraine have identified key molecular triggers like CGRP and PACAP, revolutionizing treatment options and offering hope for patients unresponsive to current therapies.
Migraine is a prevalent neurological disorder characterized by recurrent and disabling attacks of moderate to severe headache
In human models of migraine, a suspected pharmacological migraine trigger is administered either orally or via infusion to a participant with migraine or a healthy volunteer, typically within a double-blinded, randomized, placebo-controlled design